Literature DB >> 16126233

Non-apoptotic concentrations of prodigiosin (H+/Cl- symporter) inhibit the acidification of lysosomes and induce cell cycle blockage in colon cancer cells.

Wilmar Castillo-Avila1, Miguel Abal, Sylvie Robine, Ricardo Pérez-Tomás.   

Abstract

Prodigiosin (PG) is a bacterial red pigment with interesting immunosuppressive and apoptotic properties that have been partly attributed to its ability to uncouple V-ATPase through the promotion of the H+/Cl- symporter. In the present study, we investigate the effect of non-apoptotic concentrations of PG on the lysosomal-pH and on cell cycle progression in colon cancer cells. Lysosomal-pH was tested in DLD-1 cells using acridine orange vital staining. Orange granules, indicative of acidified lysosomes, decreased significantly in cells treated with 25 nM of PG for 1/2 h, and disappeared completely at 100 nM. This suggests that PG can induce lysosomal alkalinization without any apparent cytotoxic effect. Cell cycle progression was analysed in HT29 cells and we found that PG induces a blockage in the G1 phase. This blockage correlates with p21(WAF1/CIP1) induction, and it can be triggered either dependently or independently of p53. In conclusion, the reversible increase in lysosomal-pH and cytosol acidification induced by non-apoptotic concentrations of PG in colon cancer cells, suggests that the apoptotic process induced by PG can not be solely explained by changes in intracellular pH. The effect of intracellular acidification on cell cycle arrest must be analysed more exactly.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16126233     DOI: 10.1016/j.lfs.2005.04.059

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

1.  Prodigiosin inhibits Wnt/β-catenin signaling and exerts anticancer activity in breast cancer cells.

Authors:  Zhongyuan Wang; Bo Li; Liang Zhou; Shubin Yu; Zijie Su; Jiaxing Song; Qi Sun; Ou Sha; Xiaomei Wang; Wenqi Jiang; Karl Willert; Lei Wei; Dennis A Carson; Desheng Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-31       Impact factor: 11.205

2.  Zooming in on the WNT/CTNNB1 Destruction Complex: Functional Mechanistic Details with Implications for Therapeutic Targeting.

Authors:  Saskia Madelon Ada de Man; Renée van Amerongen
Journal:  Handb Exp Pharmacol       Date:  2021

3.  In -silico molecular docking analysis of prodigiosin and cycloprodigiosin as COX-2 inhibitors.

Authors:  Pabba Shiva Krishna; Kompally Vani; Metuku Ram Prasad; Burra Samatha; Nidadavolu Shesha Venkata Sathya Siva Surya Laxmi Hima Bindu; Maringanti Alaha Singara Charya; Prakasham Reddy Shetty
Journal:  Springerplus       Date:  2013-04-19

4.  Anion-Transport Mechanism of a Triazole-Bearing Derivative of Prodigiosine: A Candidate for Cystic Fibrosis Therapy.

Authors:  Claudia Cossu; Michele Fiore; Debora Baroni; Valeria Capurro; Emanuela Caci; Maria Garcia-Valverde; Roberto Quesada; Oscar Moran
Journal:  Front Pharmacol       Date:  2018-08-07       Impact factor: 5.810

Review 5.  Production and Potential Applications of Bioconversion of Chitin and Protein-Containing Fishery Byproducts into Prodigiosin: A Review.

Authors:  San-Lang Wang; Van Bon Nguyen; Chien Thang Doan; Thi Ngoc Tran; Minh Trung Nguyen; Anh Dzung Nguyen
Journal:  Molecules       Date:  2020-06-13       Impact factor: 4.411

6.  Prodigiosin-Emerged PI3K/Beclin-1-Independent Pathway Elicits Autophagic Cell Death in Doxorubicin-Sensitive and -Resistant Lung Cancer.

Authors:  Wei-Jun Chiu; Shian-Ren Lin; Yu-Hsin Chen; May-Jwan Tsai; Max K Leong; Ching-Feng Weng
Journal:  J Clin Med       Date:  2018-10-03       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.